Japan Reimburses E Keppra For Status Epilepticus After Physician Push
Executive Summary
Following an investigator-initiated clinical development program demonstrating its value, Japan has granted reimbursement to UCB's anticonvulsant E Keppra for status epilepticus, pending what appears to be the formal approval globally in this indication.